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Efforts to develop vaccines against malaria have been the focus of substantial research
activities for decades. Several categories of candidate vaccines are currently being
developed for protection against malaria, based on antigens corresponding to the pre-
erythrocytic, blood stage, or sexual stages of the parasite. Long lasting sterile protection
from Plasmodium falciparum sporozoite challenge has been observed in human following
vaccination with whole parasite formulations, clearly demonstrating that a protective
immune response targeting predominantly the pre-erythrocytic stages can develop against
malaria. However, most of vaccine candidates currently being investigated, which are
mostly subunits vaccines, have not been able to induce substantial (>50%) protection
thus far. This is due to the fact that the antigens responsible for protection against the
different parasite stages are still yet to be known and relevant correlates of protection have
remained elusive. For a vaccine to be developed in a timely manner, novel approaches
are required. In this article, we review the novel approaches that have been developed to
identify the antigens for the development of an effective malaria vaccine.
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INTRODUCTION
Malaria is an infectious disease caused by the protozoan para-
site Plasmodium and transmitted by the Anopheles mosquitoes.
Malaria is a major public health problem, leading to high mor-
tality and morbidity. Nearly half the world’s population is at
risk of contracting malaria (CDC, 2012). There are 207 million
cases of clinical malaria and approximately 627,000 deaths in
WHO (2012). There is currently no available vaccine. Age and
host immune status are high risk factors for malaria, with young
children under the age of ﬁve, pregnant women and travelers or
migrants who lack immunity to the disease being most suscepti-
ble. Other risk factors include the infectivity and the transmission
dynamics of the parasite strain (Doolan, 2011).
The Plasmodium parasite has a complex life cycle. Following an
infected mosquito bite, sporozoites are inoculated into the dermis
of the mammalian host (Vanderberg and Frevert, 2004; Amino
et al., 2006). The sporozoites travel to the liver via the blood-
stream and infect the hepatocytes (Amino et al., 2006). During
this phase in the hepatocytes, sporozoites develop into schizonts
over 2–14 days, depending on the species. Merosomes, merozoites
containing vesicles, eventually bud out from infected hepato-
cytes to release merozoites, which then infect erythrocytes (Sturm
et al., 2006; Baer et al., 2007). Some of the blood stage parasites
undergo sexual differentiation into male and female gametocytes
that can be taken up by a feeding Anopheline during a blood
meal. Ookinetes, which results from gametocyte fusion, develop
into oocysts in the midgut of the mosquito. Upon oocyst mat-
uration, newly formed sporozoites migrate to the salivary gland
of the mosquito, awaiting the next blood meal (Moorthy et al.,
2004).
Symptoms of malaria include fever, headache, chills, sweating,
and vomiting. Recurrent fever is one of the hallmarks of clinical
malaria. This is a consequence of the release of malarial toxins into
the bloodstream following repetitive rupture and re-invasion of
erythrocytes. With disease progression, the red blood cell counts
decreases and severe anemia might occur. Malarial infected red
blood cells, such as those of Plasmodium falciparum, can also
sequester in deep tissues, causing cerebral malaria, and organ
failure. These severe pathologies can eventually lead to death.
IMMUNE RESPONSES TO A MALARIA INFECTION
Protective immunity against malaria requires a timely and coordi-
nated interplay between the innate and adaptive immunity. This
involves dendritic cells, NK cells, B cells, CD4+ and CD8+ T cells
(Stevenson and Riley, 2004).
Sporozoite-speciﬁc antibodies can block sporozoites from
migrating to the liver or from invading into hepatocytes, arrest-
ing disease progression (Rathore et al., 2005; Finney et al., 2014).
Antibody-mediated immunity has been thought to be the central
effectors of parasite clearance in the peripheral blood as MHC
class I/II molecules are absent on the surface of infected red
blood cells (Langhorne et al., 2008). The importance of antibod-
ies was ﬁrst demonstrated by Cohen et al. (1961), showing that
passive transfer of immunoglobulins from immune adults into
naïve, infected children resulted in rapid reductions of parasite
density and resolution of clinical symptoms (Cohen et al., 1961).
Merozoite-speciﬁc antibodies can prevent merozoites from invad-
ing erythrocytes (Michon et al., 2000; Dutta et al., 2005; Jiang et al.,
2011) and mediate clearance of infected red blood cells by phago-
cytic cells via antibody-dependent cellular inhibition (Marsh and
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Kinyanjui, 2006). Pathogen-speciﬁc antibodies secreted by B cells
with CD4+ T helper cells enhancement are essential for clearance
of parasitemia in the later stages of the infection (Langhorne et al.,
2008).
In addition to the humoral arm of the adaptive immunity,
cell-mediated immune responses are also crucial for protection
against malaria. CD8+ and CD4+ T cells kill infected hepato-
cytes through diverse mechanisms (Renia et al., 1993; Doolan
and Hoffman, 2000; Frevert et al., 2009; Trimnell et al., 2009;
Cockburn et al., 2013) and induce sterile protection (i.e., no blood
stage infection) in mouse models. Recent work has revealed an
important role for IFNγ-secreting CD8+ T cells in preventing
chronic P. chabaudi blood stage infection in mice (Horne-Debets
et al., 2013). In human, sterile protection has been observed in
experimental sporozoite challenge experiments following vacci-
nation with whole sporozoites (Hoffman et al., 2002; Roestenberg
et al., 2009; Seder et al., 2013). Both sporozoite-speciﬁc antibodies
and T cells were induced.
VACCINE DEVELOPMENT AGAINST MALARIA
The rationale for vaccine development to protect against malaria
stems from observations where naturally acquired immunity
to malaria can protect individuals living in malaria-endemic
regions against malaria in an age-dependent and exposure-
dependent manner (Gupta et al., 1999; Schoﬁeld and Mueller,
2006; Crompton et al., 2010). Although the protection is not ster-
ilizing and is not always ensured for all chronically exposed
individuals, passive transfer of sera from some chronically exposed
individuals reduced strongly parasite levels in infected individuals
(Cohen et al., 1961; Bouharoun-Tayoun et al., 1995). This demon-
strated that antibodies can offer protection against the blood phase
of the malarial infection.
More rationally, the typical Pasteur approach where attenu-
ated parasites were used as vaccines has further demonstrated the
feasibility of vaccination as protection againstmalaria. Immuniza-
tion with irradiation-attenuated sporozoites has shown to confer
sterile immunity against sporozoites challenge in animal models
and in humans (Richards, 1966; Nussenzweig et al., 1967; Clyde
et al., 1973; Rieckmann et al., 1974; Hoffman et al., 2002). The
protective immune response involving antibodies and T cells was
shown to target the pre-erythrocytic stages (Nussenzweig et al.,
1967; Overstreet et al., 2008). In recent years, immunization with
sporozoite or blood parasite under drug cover was also shown
to confer strong protective immunity involving antibodies and T
cells (Belnoue et al., 2002; Renia et al., 2006; Roestenberg et al.,
2009; Friesen et al., 2010). Other approaches have used genet-
ically attenuated parasites. Although these approaches have led
to sterile immunity in mice (Mueller et al., 2005; Butler et al.,
2012), they have yet to prove their efﬁcacy in humans (Spring
et al., 2013).
After decades of efforts spent on developing vaccines against
malaria, no strong vaccine candidate has emerged as yet. Most
vaccine development efforts are focused on only four antigens
(WHO, 2012). The most clinically advanced candidate, RTS,S,
conferred ∼50% protection from clinical P. falciparum malaria
in children aged 5–17 months, and ∼30% protection in children
aged 6–12 weeks (Agnandji et al., 2011, 2012). Vaccine efﬁcacy
was undetectable 3 years after vaccination (Bejon et al., 2013).
This level of protection is suboptimal and too low to achieve
malaria eradication. No single molecular signature, key cellu-
lar determinant or immune mechanism of naturally acquired
or vaccine-induced immunity has been unequivocally associated
with protection (Offeddu et al., 2012). This impediment toward
vaccine development for malaria is multi-factorial. The Plasmod-
ium parasite has a diverse protein repertoire, and a complex life
cycle involving both vertebrate and invertebrate hosts. There are
antigenic polymorphisms and variations across parasite strains
and species, and the parasite has developed sophisticated strategies
to evade the host immunity.
With more reports of drug resistance and insecticide resistance
in some endemic regions (Trape et al., 2011; Phyo et al., 2012;
Ashley et al., 2014), management of the malarial disease has been
increasingly difﬁcult. Identiﬁcation of new malarial antigens for
vaccine development is critical. Here, we reviewed the different
techniques that have been used to identify antigens recognized by
antibodies induced during natural infections or after vaccinations
with whole parasites.
PRE-GENOMIC SCREENING METHODS FOR PROTECTIVE
ANTIGENS
The advent of new molecular biology techniques in the 1980s led
to the discovery of many Plasmodium antigens. DNA libraries,
consisting of cDNA or genomic DNA, were constructed in bac-
teriophage vectors for expression in Escherichia coli (Kemp et al.,
1986). Antigens such as the circumsporozoite protein (CSP), the
S-antigen, the ring erythrocyte surface antigen (RESA) were the
ﬁrst to be identiﬁed using mouse monoclonal antibodies (Ellis
et al., 1983), sera from infected humans (Kemp et al., 1983; Stahl
et al., 1984) or sera from infected mice or monkeys (Anders et al.,
1984; Brown et al., 1984; Ardeshir et al., 1985). All the antigens
discovered using these approacheswere immunodominant or pos-
sessed immunodominant regions made of repeats (Kemp et al.,
1987). Although immunodominant antigens induce very strong
antibody responses, recent studies have shown that they did not
offer adequate protection when tested as subunit vaccines in clini-
cal trials (Spring et al., 2009; Doolan, 2011; Sheehy et al., 2012),
suggesting that these antigens might be used by the Plasmod-
ium parasite for immune evasion (Anders, 1986; Rodriguez et al.,
2008). The CSP, an antigen of pre-erythrocytic stage malaria and
the ﬁrst malaria antigen to be cloned (Ellis et al., 1983), is one such
example. Despite being immunodominant, the Phase III vaccine
efﬁcacy was suboptimal, with 55% reduction in the frequency of
malaria episodes during the 12 months of follow-up in children
5–17 months of age and 35% in children 6–12 weeks old at ﬁrst
immunization (Agnandji et al., 2011). The protection waned to
a mere 16.8% after 4 years of follow-up, indicating the lack of
long lasting protection which declined with time and exposure
to the parasite (Olotu et al., 2013). Similarly, while immuniza-
tion with the apical membrane antigen-1 (AMA-1), an antigen
expressed both at the pre-erythrocytic and erythrocytic stages and
strongly immunodominant during the erythrocytic stage, elicited
functional antibodies with in vitro inhibition against homologous
blood parasites, volunteers developed parasitemia upon challenge
with controlled human malaria infection (infection by mosquito
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bites)without a signiﬁcant reductionof peakparasitemia nor delay
to patency (Spring et al., 2009).
The cDNA library approach is advantageous with a good rep-
resentation of a stage-speciﬁc Plasmodium proteome, depending
on the stage of the parasite at which the RNA was extracted from.
However, the repertoire of the Plasmodium proteome the cDNA
library represents is not entirely comprehensive and does not
include antigens expressed by the parasite in the other stages of
its life cycle. Nevertheless, it has successfully identiﬁed more than
a hundred malaria antigens. Recently, Raj et al. (2014) created a
P. falciparum blood stage cDNA library constructed in bacterio-
phage and expressed in E. coli. The antigen library was screened
against sera from either infection-resistant or – susceptible chron-
ically exposed individuals living in malaria-endemic regions. 2
out of 3 antigens identiﬁed were novel antigens. Antibody to
one of the identiﬁed novel antigens, PfSEA-1, inhibited parasite
growth and blocked schizont egress. Using the P. berghei ANKA
strain ortholog of PfSEA-1, the authors demonstrated reduced
parasitemia and longer survival in mice vaccinated with PbSEA-1.
They further validated PfSEA-1 as a promising vaccine candidate
through epidemiological studies, where anti-PfSEA-1 antibodies
were strongly associated with lesser incidence of severe malaria
in Tanzanian children and lower level of parasitemia in Kenyan
adults.
SCREENING METHODS TO IDENTIFY NEW ANTIGENS IN THE
ERA FOLLOWING GENOME SEQUENCING
At the turn of the 20th century, whole genomes of many Plasmod-
ium strains were sequenced. These genome sequencing initiatives,
by The Wellcome Trust Sanger Institute and The Institute for
Genomic Research, have provided a wealth of data for the identi-
ﬁcation of protective antigens (Carlton et al., 2002; Gardner et al.,
2002). In this review, we discuss the novel approaches (summa-
rized in Table 1) to screen libraries of malarial antigen using sera
from protected versus unprotected individuals to identify antigens
associated with protection, in search for new protective antigens
for vaccine development against malaria.
NEW APPROACHES TO SEARCH FOR ANTIGENS INVOLVED
IN PROTECTION
The availability of whole genome sequences has enhanced the
understanding of the parasite biology. Protein functions can be
predicted and validated. Potential antigens could be screened for
speciﬁc characteristics such as surface expression. Comparative
genomics between different parasite strains allows identiﬁcation
of antigens that have limited variation, with the promise of greater
vaccine coverage and hence efﬁcacy in the ﬁeld (Kooij et al.,
2005).
Transcriptomics and proteomics has provided critical infor-
mation on the expression proﬁles of malarial proteins during
the parasite’s life cycle (Florens et al., 2002; Le Roch et al., 2002;
Bozdech et al., 2003; Hall et al., 2005) – the mosquito stage
(Lindner et al., 2013), the liver stage (Tarun et al., 2008), and the
sexual stage (Lasonder et al., 2002; Khan et al., 2005). In silico
analysis of stage-speciﬁc transcription pattern identiﬁes antigens
that are differentially expressed for speciﬁc targeting to a speciﬁc
stage of the parasite’s life cycle and also antigens with conserved
expression across the different stages for cross-stages targeting
(Florens et al., 2002).
SCREENING RECOMBINANT PROTEIN MICROARRAYS AGAINST
IMMUNE SERA FROM VACCINATED HUMAN INDIVIDUALS
Using the published P. falciparum and P. vivax genomes, a set
of selected genes was targeted for protein expression using an in
vitro transcription/translation system (Doolan et al., 2008; Tsuboi
et al., 2008; Crompton et al., 2010; Barry et al., 2011; Trieu et al.,
2011; Molina et al., 2012; Baum et al., 2013; Lu et al., 2014). These
recombinant proteins were then printed onto microarray chips
andprobedwith immune sera thatwere obtained fromhumanvol-
unteers naturally exposed tomalaria infections or immunizedwith
radiation-attenuated sporozoites. Doolan et al. (2008) generated a
protein microarray with 250 P. falciparum proteins and used it to
proﬁle antibody responses in sera from four groups of individuals:
(1) protected, (2) non-protected individuals following vaccina-
tion with radiation-attenuated sporozoites, (3) partially protected
individuals due to natural exposure, and (4) non-exposed indi-
viduals. The same group then expanded their library to include
1204 P. falciparum proteins (representing 23% of the P. falci-
parum genome; Crompton et al., 2010; Trieu et al., 2011; Baum
et al., 2013) and also 91 P. vivax proteins (Molina et al., 2012).
22–29% of the screened proteins were found to be serodominant
in immune sera, demonstrating a broad and varied response to
many antigens. Antibody titres against current vaccine candidates
such as CSP, atypical membrane antigen-1, liver stage antigen-
3, merozoite surface protein-1 did not differ between immune
and non-immune individuals (Crompton et al., 2010; Trieu et al.,
2011).
Richards et al. (2013) expressed P. falciparum merozoite pro-
teins, reported to have a role in erythrocyte invasion and/or
localized on the merozoite surface or in the invasion organelles
of the merozoites, in either bacterial or wheat germ cell-free
expression systems. The recombinant proteins were tested for IgG
immunoreactivity using sera from malaria-exposed Papua New
Guinea children in ELISA. Forty six proteins were selected based
on their ability to coat ELISA plates and their immunoreactivity.
Sera from older children had higher immunoreactivity to most of
the 46 proteins as compared to the younger children, indicating
an acquisition of antibody responses with age, presumably due
to prolonged exposure to the parasite. While merozoite surface
proteins had higher seropositivity compared to the rhoptry and
micronemal proteins, the antigens strongly correlatedwith protec-
tion were the rhoptry and micronemal proteins. This is consistent
with other studies, suggesting that the key protective malarial
antigens are the non-immunodominant antigens (Doolan et al.,
2003, 2008; Crompton et al., 2010; Trieu et al., 2011; Baum et al.,
2013). The authors proposed that a combinational vaccine consist-
ing of non-immunodominant antigens, such as EBA, PfRh2 and
PfRh4, is more likely to offer greater protection (Richards et al.,
2013).
One of the main drawbacks with protein array is the exten-
sive efforts needed to generate the soluble recombinant malarial
antigens in the library (Doolan et al., 2008; Tsuboi et al., 2008).
Cell-based expression systems have met with many difﬁculties. P.
falciparum genes have a highA/T content and a substantial number
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Table 1 | Approaches taken to identify protective malarial antigens for vaccine development.
Type of antigen
library
Antigen
expression
system
Size of
library
Type of
screening
Sera/antigens that library
is screened against
Reference
Pre-genomic era cDNA E. coli cell-based In vitro
immunoscreen
Mouse monoclonal
antibodies
Ellis et al. (1983)
cDNA E. coli cell-based 10 000 clones In vitro
immunoscreen
Sera from infected human
individuals
Kemp et al. (1983),
Brown et al. (1984),
Stahl et al. (1984)
cDNA E. coli cell-based 10 000 clones
10 000 clones
9 000 clones
In vitro
immunoscreen
Sera from infected mice,
mice and rabbits,
monkeys
Brown et al. (1984)
Anders et al. (1984)
Ardeshir et al. (1985)
Post-genomic era cDNA E. coli cell-based 1 250 000
clones
In vitro
immunoscreen
Sera from infection-resistant
and –susceptible chronically
exposed human individuals
Raj et al. (2014)
Recombinant
proteins
E. coli cell-free in
vitro translation
250 antigens In vitro
immunoscreen
Sera from protected and
non-protected individuals
following vaccination with
radiation-attenuated
sporozoites
Doolan et al. (2008)
Recombinant
proteins
E. coli cell-based
and wheat germ
cell-free system
46 antigens In vitro
immunoscreen
Sera from malaria-exposed
children
Richards et al. (2013)
Antigens
expressed on cell
surface
Mammalian
cell-based
80 antigens In vitro
immunoscreen
Sera from protected and
non-protected individuals
following vaccination with
live sporozoites
Chia et al. (2014)
Whole parasite
lysates
P. yoelii parasite Whole
proteome
In vitro
immunoscreen
Afﬁnity-puriﬁed IgG from
immune mice that naturally
survived a lethal infection
Kamali et al. (2012)
DNA (exons) – 19 genes In vivo screen in
mice for
protection
– Haddad et al. (2004)
Recombinant
proteins
Mammalian
cell-based
51 antigens In vitro
protein–protein
interaction screen
Malarial antigen, PfRh5 Crosnier et al. (2011)
of the genes encode stretches of repeat sequences (Gardner et al.,
2002), hindering protein expression in cell-based expression sys-
tem. Only 30% out of 1000 genes investigated by Mehlin et al.
(2006) can be expressed in E. coli and a mere 6.3% of the proteins
are soluble. The alternative is the wheat germ cell-free expression
system. Tsuboi et al. (2008) were able to express 93 out of 124 P.
falciparum genes as soluble proteins using the wheat germ cell-
free system. Rui et al. (2011) reported greater immunogenicity of
wheat germ proteins (as opposed to identical proteins produced
in E. coli) in mice. The wheat germ cell-free expression sys-
tem could be more suitable for producing antigens for vaccine
development.
SCREENING CELL-ASSOCIATED ANTIGEN LIBRARIES AGAINST
IMMUNE MOUSE SERA
We recently cloned a library of 80 malarial antigens into a mam-
malian surface expression vector pDisplay (Invitrogen; Chia et al.,
2014). They transfected these expression vectors into mammalian
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cells and the antigens were expressed on the cell surface, creat-
ing a library of antigen-presenting cells. The library was screened
against immune and non-immune sera obtained from mice
immunized with live sporozoites or blood parasites under drug
cover (Belnoue et al., 2008). Similarly, all immunized volunteers in
the studywere protected from sporozoites challenge. The antibody
repertoire of immunized volunteers was extremely broad and var-
ied. MAEBL was found to be strongly associated with protection.
MAEBLhas been implicated in invasion intohepatocytes by sporo-
zoites and merozoites into erythrocytes (Kappe et al., 1998, 2001).
It was previously demonstrated that anti-MAEBL antibodies to
inhibitP. yoelii sporozoites invasion in vitro in primarymouse hep-
atocytes, suggesting that MAEBL is a promising attractive vaccine
candidate (Singh et al., 2004).
This approach removes the difﬁculty of expressing and purify-
ing antigens as soluble recombinant proteins. However, the library
size in this study represents a small representation of the entire
Plasmodium genome (∼1%) and antigens screened were mainly
restricted to those with reasonably good transfection efﬁciency.
SCREENING WHOLE PARASITE LYSATES AGAINST AFFINITY-PURIFIED
IgG FROM NATURALLY SURVIVING MICE
Due to ethical and technical restrictions, identiﬁcation of protec-
tive immune correlates in humans can only be evaluated in the
peripheral blood component. This hinders the study of a vital
stage of the parasite’s life cycle, the liver stage. It also limits the
examination of the host immune responses in the secondary lym-
phoid organs such as the spleen, which are also important sites for
the induction of protective immunity.
The use of comparative genomic analysis, through the con-
struction of genome-wide synteny maps, has identiﬁed other
non-human models of malaria (Carlton et al., 2002; Tachibana
et al., 2012). Mouse models have played a vital role in the under-
standing of the immunobiology of malarial infections. The mouse
malaria parasite, P. yoelii, has been used as a model for malaria
research due to the substantial similarity to the human parasite
P. falciparum (Hall et al., 2002). In addition to being cheaper to
maintain and easier to handle, the mouse also has a well char-
acterized immune system, hence offering great advantages over
non-human primate models (Wykes and Good, 2009; Taylor-
Robinson, 2010). Infection studies of rodent malaria species and
their hosts have provided information on parasite biology and
pathogenicity. Identiﬁcation of orthologs allows preclinical vali-
dation of new chemotherapies and vaccine candidates. The lethal
P. yoelii model, which causes death in BALB/c mice, is an excellent
model for investigating the vaccine efﬁcacy of the candidates in
vivo (Langhorne, 1994). Kamali et al. (2012) observed that 20%
of ICR mice infected with the lethal strain of P. yoelii cleared the
infection and these naturally surviving mice had boosted immu-
nity following a second challenge. They afﬁnity-puriﬁed the IgG
from these mice and probed against whole parasite lysates. Using
MALDI-TOF analysis, the antigenic speciﬁcities of the protec-
tive IgG were Heat shock protein 70 (HSP70), protein disulphide
isomerase, plasmepsin and a 39 kDa subunit of eukaryotic trans-
lation initiation factor 3. Although the authors did not validate
the protective potential of the identiﬁed antigens, the approach
used in the study identiﬁed novel antigens (with the exception of
PfHSP70.1 (Haddad et al., 2004). Antibodies against PfHSP70.1
have been shown to eliminate in vitro liver stage parasites through
antibody-dependent cell-mediated cytotoxic mechanisms (Renia
et al., 1990).
SCREENING FOR PROTECTIVE DNA VACCINE CANDIDATE IN MOUSE
CHALLENGE MODEL
New molecular technologies such as Gateway cloning make it
easy to clone large numbers of genes into plasmids. Using this
technology, Haddad et al. (2004) produced an expression library
of 182 Plasmodium exons coding for pre-erythrocytic antigens
in the mammalian immunization vector VR1012. They immu-
nized mice with 19 out of the 182 cloned vectors, either singly
or in combination, and assessed vaccine efﬁcacy following sporo-
zoites challenge by examining the ability of the immunized mice
to reduce liver stage parasite load. The most promising DNA vac-
cine candidate identiﬁed was Py01316, annotated as a Qa-SNARE
protein in PlasmoDB, which gave a 68–79% reduction in parasite
load.
The approach taken by Haddad et al. (2004) has the beneﬁt of
generating a library of DNA vaccine candidates, targeting many
Plasmodium genes with great ease, and does not require the labo-
rious process of generating recombinant proteins. It also provides
information on the immunogenicity of the DNA constructs and
in vivo effectiveness of the induced immune responses to reduce
parasite load. However, screening for protective DNA vaccine tar-
gets in mice is laborious and requires a large number of mice. As
a result, the authors screened a total of 19 out of the 182 cloned
plasmids, which limited the number of malarial antigens that can
be validated for protective efﬁcacy.
TARGETED SCREENING TO IDENTIFY MALARIAL ANTIGENS AND THEIR
RECEPTORS
Crosnier et al. (2011) expressed a library of erythrocyte sur-
face proteins with the mammalian expression system. Using
the avidity-based extracellular interaction screen (AVEXIS), they
screened recombinant PfRh5 protein (the bait protein), which is
critical for erythrocyte invasion by merozoites, against the library
of erythrocyte surface proteins (the prey protein). The PfRh5
protein was found to interact with only one erythrocyte surface
protein, basin. The anti-basin monoclonal antibodies were highly
effective at blocking P. falciparum invasion into erythrocytes ex
vivo and these blocking effects were efﬁcacious with 15 other
culture-adapted and ﬁeld strains of P. falciparum. These data have
implications for novel therapeutics. While this does not directly
identify new protective malarial antigens for vaccine development,
the identiﬁcation of basin as the binding partner of PfRh5 and
perhaps further characterisation studies on the expression levels
of basin by the target population would provide critical informa-
tion on the vaccine efﬁcacy of PfRH5, should PfRh5 be developed
as a vaccine candidate. Understanding how basigin binds to PfRh5
could also facilitate rational design of drug compounds to block
P. falciparum’s invasion into erythrocytes.
One of the shortcomings of AVEXIS is the generation of the
library of recombinant proteins, which is laborious. This approach
also requires theprior identiﬁcationof a knownbait protein,which
is difﬁcult for identifying novel host–parasite interacting antigen
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pairs. However, the AVEXIS assay is advantageous in its ability to
detect direct low-afﬁnity protein interactions, which might not be
detectable in other screening methods. More recently, this type of
library has shown to be a powerful tool to identify new protective
antigens for potential vaccine target development. Using sera from
a longitudinal study in a cohort of Kenyan children, Osier et al.
(2014) identiﬁed 10 antigens (PF3D7_1136200, MSP2, RhopH3,
P41, MSP11, MSP3, PF3D7_0606800, AMA1, Pf113, and MSRP1)
that were associated with protection against clinical episodes of
malaria. While the AVEXIS approach has been used to identify
blood stage antigens in this study, the study could be extended to
include antigens for other stages.
IDENTIFICATION OF PROTECTIVE PRE-ERYTHROCYTIC ANTIGENS
Pre-erythrocytic antigens have been attractive targets for vaccine
development. This is mainly due to the demonstration that sterile
immunity against malaria is achievable in experimental sporo-
zoite challenge experiments in humans following vaccination with
whole sporozoites (Hoffman et al., 2002; Roestenberg et al., 2009;
Seder et al., 2013).
Most of the above described approaches for identiﬁcation
of protective antigens have used sera from chronically exposed
individuals living in endemic regions to screen for protective
malarial antigens. Although the approaches have identiﬁed mainly
blood stage antigens, some of the identiﬁed blood stage antigens,
such as AMA1 (Silvie et al., 2004), TRAP (Robson et al., 1995),
EBA175 (Gruner et al., 2001b), PfEMP3 (Gruner et al., 2001a),
and HSP70.1 (Renia et al., 1991), which are also expressed during
the liver stage.
To screen for protective pre-erythrocytic antigens, it is essen-
tial to have the appropriate sera sets against which the library
of malarial antigens will be screened. While sera from chroni-
cally exposed individuals living in endemic regions are relatively
easier to obtain, they are more likely to have an antibody reper-
toire that is predominantly speciﬁc for blood stage antigens,
hence might not be suitable for the identiﬁcation of liver stage
antigens. Marchand and Druilhe (1990) and Gruner et al. (2003)
were the ﬁrst to show in human that chloroquine prophylaxis
protected against blood stage infection and use the protected sera
to screen for protective antigens. This led to the identiﬁcation of
liver-speciﬁc (LSA1; Guerin-Marchand et al., 1987) or cross stage-
speciﬁc antigens stages (LSA-3, STARP, and SALSA; Fidock et al.,
1994; Bottius et al., 1996; Daubersies et al., 2000). Recently, the
studies by Trieu et al. (2011) and Chia et al. (2014) involved the
use of sera from animals immunized with sporozoites. Trieu et al.
(2011) identiﬁed 16 previously uncharacterized pre-erythrocytic
antigens (Trieu et al., 2011), while the pre-erythrocytic MAEBL
antigen was identiﬁed by Chia et al. (2014).
CONCLUSION
Historically, vaccine development efforts have been focused on
immunodominant antigens as vaccine candidates such as mero-
zoite or sporozoite surface proteins. However, the success has been
limited thus far.
More recently, through the use of new technologies, immuno-
screens have become more comprehensive, and has revealed the
strong association of non-immunodominant malarial antigens
with protection. Antigen libraries, expressed in bacterial, mam-
malian, or wheat germ cell-free expression systems, are created
either as DNA libraries, recombinant proteins or on cell surface as
antigen-presenting cells. In the screening of these antigen libraries
for protective antigens, immune sera are an important tool. The
type of immune sera chosen for the screening is critical. Carefully
planned vaccination trials with an experimental challenge provide
differential groups of sera from protected versus non-protected
vaccinated individuals to identify protective antigens. Sera from
chronically exposed individuals living in malaria-endemic regions
have been also used in studies to screen for protective antigens.
While sera from these individuals inform about naturally acquired
immunity, it is essential to differentiate between the susceptible
and the resistant individuals in thesenaturally exposed individuals.
These differential sera allow the exclusion of immunodominant
antigens, and inclusion of the non-immunodominant antigens
that are associated with protection.
Taken together, the current consensus is protection against
malaria is attributed to robust humoral responses directed against
a panel of various non-variant antigens instead of only a single
or a few immunodominant antigens. Studies to validate the feasi-
bility of these minor non-immunodominant antigens as vaccine
candidates should be prioritized for vaccine development against
malarial infections. In addition, understanding antigen recog-
nition is an essential step for the establishment of key immune
correlates of protection against malarial infections, which would
aid greatly in validating vaccine efﬁcacy.
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